GALT:NSD-Galectin Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.65

Change

+0.02 (+0.76)%

Market Cap

USD 0.18B

Volume

0.14M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing GALT

CHDIV:SW UBS ETF (CH) - MSCI Switz.. 6.87 % 0.00 %

-0.02 (-0.12%)

USD 1,244,681.59B
FSZ First Trust Switzerland A.. 4.05 % 0.80 %

+1.13 (+-0.12%)

USD 0.09B
EESM:PA BNP Paribas Easy MSCI Eur.. 2.07 % 0.00 %

+4.77 (+-0.12%)

USD 0.14B
EESM:XETRA BNP Paribas Easy MSCI Eur.. 2.07 % 0.00 %

+4.60 (+-0.12%)

USD 0.22B
CEM:PA Amundi MSCI Europe Small .. 0.79 % 0.00 %

+1.97 (+-0.12%)

USD 0.13B
X026:XETRA Amundi MSCI Europe Small .. 0.79 % 0.00 %

+0.86 (+-0.12%)

USD 0.11B
EESM:F BNP Paribas Easy - MSCI E.. 0.00 % 0.00 %

+5.05 (+-0.12%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.64% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.64% 85% B 91% A-
Trailing 12 Months  
Capital Gain 39.47% 73% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.47% 73% C 80% B-
Trailing 5 Years  
Capital Gain -27.00% 61% D- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.00% 60% D- 32% F
Average Annual (5 Year Horizon)  
Capital Gain 9.61% 65% D 66% D+
Dividend Return 9.61% 65% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.77% 41% F 22% F
Risk Adjusted Return 12.20% 72% C 49% F
Market Capitalization 0.18B 56% F 46% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector